Ken Griffin Alkermes Plc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Alkermes Plc. stock. As of the latest transaction made, Citadel Advisors LLC holds 17,000 shares of ALKS stock, worth $600,440. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,000

Previous 18,500 8.11%

Holding current value

$600,440

Previous $517,000 5.61%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$25.7 - $31.46 $763,752 - $934,928	-29,718 Reduced 35.84%	53,206 $1.53 Million
Q3 2024 Nov 14, 2024	SELL	$23.01 - $28.55 $5.51 Million - $6.83 Million	-239,290 Reduced 74.26%	82,924 $2.32 Million
Q2 2024 Aug 14, 2024	BUY	$23.21 - $27.24 $6.22 Million - $7.3 Million	267,931 Added 493.58%	322,214 $7.77 Million
Q1 2024 May 15, 2024	BUY	$26.4 - $32.56 $1.43 Million - $1.77 Million	54,283 New	54,283 $1.47 Million
Q3 2023 Nov 14, 2023	SELL	$27.17 - $31.97 $30 Million - $35.3 Million	-1,102,707 Reduced 74.43%	378,762 $10.6 Million
Q2 2023 Aug 14, 2023	SELL	$28.34 - $33.63 $56.8 Million - $67.4 Million	-2,003,150 Reduced 57.49%	1,481,469 $46.4 Million
Q1 2023 May 15, 2023	SELL	$25.31 - $29.02 $74.5 Million - $85.4 Million	-2,943,669 Reduced 45.79%	3,484,619 $98.2 Million
Q4 2022 Feb 14, 2023	BUY	$21.94 - $26.24 $60.2 Million - $72.1 Million	2,746,011 Added 74.57%	6,428,288 $168 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $19.8 Million - $28.7 Million	899,970 Added 32.35%	3,682,277 $82.2 Million
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $11.6 Million - $13.4 Million	439,328 Added 18.75%	2,782,307 $82.9 Million
Q1 2022 May 16, 2022	BUY	$23.07 - $27.99 $38.9 Million - $47.2 Million	1,684,879 Added 256.02%	2,342,979 $61.6 Million
Q4 2021 Feb 14, 2022	BUY	$21.47 - $32.08 $2.24 Million - $3.34 Million	104,142 Added 18.8%	658,100 $15.3 Million
Q3 2021 Mar 11, 2022	BUY	$23.37 - $32.13 $12.9 Million - $17.8 Million	553,958 New	553,958 $17.1 Million
Q3 2021 Nov 15, 2021	SELL	$23.37 - $32.13 $6.14 Million - $8.45 Million	-262,920 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$18.78 - $25.15 $916,877 - $1.23 Million	-48,822 Reduced 15.66%	262,920 $6.45 Million
Q1 2021 May 17, 2021	BUY	$18.21 - $23.2 $3.08 Million - $3.92 Million	169,049 Added 118.47%	311,742 $5.82 Million
Q4 2020 Feb 16, 2021	BUY	$15.39 - $22.1 $973,802 - $1.4 Million	63,275 Added 79.67%	142,693 $2.85 Million
Q3 2020 Nov 16, 2020	BUY	$16.16 - $20.66 $619,461 - $791,959	38,333 Added 93.3%	79,418 $1.32 Million
Q2 2020 Aug 14, 2020	SELL	$13.31 - $19.41 $7.93 Million - $11.6 Million	-596,063 Reduced 93.55%	41,085 $797,000
Q1 2020 May 15, 2020	SELL	$13.06 - $21.24 $4.03 Million - $6.55 Million	-308,443 Reduced 32.62%	637,148 $9.19 Million
Q4 2019 Feb 14, 2020	SELL	$17.29 - $21.74 $6.05 Million - $7.6 Million	-349,786 Reduced 27.0%	945,591 $19.3 Million
Q3 2019 Nov 14, 2019	BUY	$19.51 - $24.28 $14.7 Million - $18.4 Million	755,854 Added 140.1%	1,295,377 $25.3 Million
Q2 2019 Aug 14, 2019	BUY	$21.47 - $37.33 $9.17 Million - $15.9 Million	427,099 Added 379.9%	539,523 $12.2 Million
Q1 2019 May 15, 2019	SELL	$28.4 - $36.49 $3.5 Million - $4.49 Million	-123,083 Reduced 52.26%	112,424 $0
Q4 2018 Feb 14, 2019	BUY	$27.94 - $44.61 $4.19 Million - $6.68 Million	149,798 Added 174.78%	235,507 $6.95 Million
Q3 2018 Nov 13, 2018	SELL	$38.6 - $46.12 $5.93 Million - $7.09 Million	-153,734 Reduced 64.2%	85,709 $0
Q2 2018 Aug 10, 2018	BUY	$40.56 - $51.36 $6.56 Million - $8.3 Million	161,671 Added 207.88%	239,443 $0
Q1 2018 May 11, 2018	BUY	$53.61 - $67.26 $4.17 Million - $5.23 Million	77,772 New	77,772 $4.51 Million

Others Institutions Holding ALKS

# of Institutions

375

Shares Held

173M

Call Options Held

231K

Put Options Held

158K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.8B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account